TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) – Drugs in Development, 2021

According to the recently published report 'TGF Beta Receptor Type 2 – Drugs in Development, 2021'; TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 7 molecules.

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) – Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene. It regulates physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of TGFBR1 and 2 TGFBR2 molecules results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2.

The report 'TGF Beta Receptor Type 2 – Drugs in Development, 2021' outlays comprehensive information on the TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 2 respectively. Report covers products from therapy areas Oncology, Respiratory, Central Nervous System, Dermatology and Genetic Disorders which include indications Pancreatic Cancer, Solid Tumor, Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Bronchopulmonary Dysplasia, Duchenne Muscular Dystrophy, Epithelial Tumor, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Nasopharyngeal Cancer, Neurodegenerative Diseases, Non-Small Cell Lung Cancer, Pulmonary Fibrosis, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma, Scar, Squamous Non-Small Cell Lung Cancer and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30)

– The report reviews TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects

– The report assesses TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Auxagen Inc

InteRNA Technologies BV

Jiangsu Hengrui Medicine Co Ltd

Oncodesign SA

Oncotelic Inc

Velvio GmbH

Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Overview

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Companies Involved in Therapeutics Development

Auxagen Inc

InteRNA Technologies BV

Jiangsu Hengrui Medicine Co Ltd

Oncodesign SA

Oncotelic Inc

Velvio GmbH

Xencor Inc

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Drug Profiles

Antisense Oligonucleotide to Inhibit TGFB2 for Duchenne Muscular Dystrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bi-specific Monoclonal Antibody to Antagonize PD1 and TGFBR2 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miRNA-520f - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVP-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-1701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Transforming Growth Factor Beta Receptor II for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize TGFBR1, TGFBR2 for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Dormant Products

TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC

2.7.11.30) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Auxagen Inc, 2021

Pipeline by InteRNA Technologies BV, 2021

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021

Pipeline by Oncodesign SA, 2021

Pipeline by Oncotelic Inc, 2021

Pipeline by Velvio GmbH, 2021

Pipeline by Xencor Inc, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports